Zhengzhi Liu, Jinling Xue, Qiaohuan Deng, Yanli Wang, Lixiu Zhang, Lang Liu, Nan Xiao, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang, Yannan Zhou, Wei Yang, Xinyao Qu, Jiahui Chen, Yicheng Zhao, Zeyu Wang, Haimiao Yang
Latuda® is a novel antipsychotic drug for schizophrenia and bipolar depression. A bioequivalence trial was performed to investigate the bioequivalence of Latuda® and its generic drug lurasidone. Two independent trials were carried out, each involving 28 subjects. In the fasting trial, subjects were randomly assigned to two groups (1:1 ratio), receiving either 40 mg of generic lurasidone or Latuda® . After a 7-day washout period, subjects entered the second period with a crossover administration of 40 mg of generic lurasidone or Latuda® ...
April 21, 2024: Naunyn-Schmiedeberg's Archives of Pharmacology